Study record
Senolytics decrease senescent cells in humans: D+Q in diabetic kidney disease (Hickson et al., 2019)
Human open-label pilot (feasibility / biomarker)
○ Evidence tier 3 — Human open-label pilot (feasibility / biomarker)
Record
| Design | Open-label Phase 1 pilot |
| N | 9 |
| Registry | NCT02848131 |
| PMID | 31542391 |
| DOI | 10.1016/j.ebiom.2019.08.069 |
| Citation status | pmid+doi verified via PubMed eutils (EBioMedicine 2019;47:446-456; PMC6796530). Erratum: EBioMedicine 2020;52:102595 (PMID 31982828) — cite corrected values; NCT02848131 from websearch |
Five-qualifier claim
| Species / population | Adults with diabetic kidney disease (n=9), open-label Phase 1 pilot. |
| Exposure, route, schedule | Oral dasatinib 100 mg + quercetin 1000 mg daily for 3 consecutive days. |
| Comparator / duration | Single-arm; adipose and skin biopsies taken ~11 days after dosing. |
| Endpoint / numeric result | Reduced senescent-cell markers (p16INK4a, p21, SA-beta-gal) and SASP factors in adipose tissue and skin — first human evidence that senolytics reduce senescent-cell burden. |
| What it did NOT establish | Biomarker change only; no clinical/renal outcome and no lifespan outcome established. A published corrigendum revised some values. |
Interventions
Primary reference
https://clinicaltrials.gov/study/NCT02848131
Exact identifier to be confirmed against the primary record before publication where flagged above.